Latest Fludarabine Stories
New IMBRUVICA Data from National Institutes of Health Study Published in The Lancet Oncology SUNNYVALE, Calif., Jan. 5, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia.
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL).
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of older patients with chronic lymphocytic leukemia (CLL).
Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies.
SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients.
The monoclonal antibody rituximab given in addition to a standard chemotherapy regimen, significantly prolongs the lives of patients with chronic lymphocytic leukemia, a new study shows.
PITTSBURGH, Oct. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma received final approval from the U.S.